Is There a Connection Between Cataracts and Dementia?

April 19, 2022Neelem Sheikh

Your eyes and your vision are very strongly connected to your brain, but just how strong is this connection? We know that changes in brain function can result in changes in vision, but what happens to brain function when there are vision changes?

A study published on December 6, 2021, by JAMA Internal Medicine found a significant association between cataract removal and a reduced risk of dementia development.

Below, we take a closer look at the research surrounding the connection between cataracts and dementia, explore hypotheses for how cataract removal impacts dementia risk, and discuss what this means moving forward.

Understanding the Link Between Visual Impairment, Cataracts, and Dementia

Throughout the past decade, there has been an increase in research surrounding new potential risk factors for Alzheimer’s-related dementia and other causes of dementia, with visual impairments being one of them.

A 2014 nationwide population-based cohort study assessed the association between cataract surgery with subsequent development of dementia in older adults with newly diagnosed cataracts. They found that the rate of dementia was significantly lower in the cataract surgery group, suggesting removing cataracts reduces dementia risk.

A 2018 longitudinal study aimed to assess how visual impairments and cognitive function are associated with each other over time. In this study of 2,520 older adults, visual impairment was associated with declining cognitive function cross-sectionally as well as over time, with worsening vision having a stronger correlation with declining cognition.

A 2020 five-year follow-up study assessing the association of glaucoma and cataracts with incident dementia found that glaucoma is an independent risk factor for incident dementia and Alzheimer’s disease, and the comorbidity of glaucoma and cataracts may significantly increase the risk of dementia and Alzheimer’s.

Finally, the study that has the Alzheimer’s and dementia prevention community talking: the 2021 JAMA Internal Medicine study assessing the association between cataract extraction and the development of dementia. The study assessed 3,038 adults aged 65 years or older with cataracts enrolled in the Adult Changes in Thought study. Even after adjusting for additional influential variables, such as years of education, race, smoking history, sex, and age at cataract diagnosis, the study found that individuals who underwent cataract removal surgery had nearly a 30% lower risk of developing dementia compared to those without the surgery. This suggests a highly significant association between cataracts and dementia risk.

How Cataract Removal Impacts Dementia Risk

Recently, researchers have associated dementia risk with conditions such as cataracts, other causes of visual impairment, and even hearing loss. What remains rather unclear is how such conditions may contribute to an increased risk of developing dementia, though several hypotheses have been proposed. Here are three proposed hypotheses for how cataract removal reduces the risk of dementia development:

  • Cataracts may decrease neuronal input, potentially accelerating neurodegeneration, and ultimately leading to cognitive decline. With vision loss comes structural changes to the visual cortex—these changes are hypothesized to lessen the input to the brain, leading to brain shrinkage, a known risk factor for dementia.
  • Compensation for a visual input deficit may increase the cognitive load and exacerbate cognitive decline.
  • Visual impairment may lead to several psychosocial challenges, such as withdrawal from social interactions, reduction in exercise or activity, or depression, all of which are well-established risk factors for dementia.

What This Means Moving Forward

The prevalence of cataracts in individuals 70 and older is quite high: 

  • Americans between the ages of 70 and 74 have a 36.5% cataract rate.
  • Americans between the ages of 75 and 79 have a 49.5% cataract rate.
  • Americans aged 80+ have a 63.8% cataract rate.

With such staggering rates, this emerging research surrounding the connection between cataracts and dementia has important implications. These findings bolster earlier research suggesting that vision loss, as well as hearing loss, are important risk factors for dementia. 

Like many other diseases and disorders, early intervention and early treatment of Alzheimer’s and other causes of dementia are likely to produce better health outcomes. People with cataracts and other visual impairments, as well as those who have other risk factors for dementia, should be regularly assessed for changes in brain function to enable the earliest possible detection.

Altoida: Creating the New Gold Standard in Brain Health

At Altoida, we are dedicated to providing a reliable, accessible, and highly accurate way to measure and monitor your brain health. 

We are building the world’s-first Precision Neurology platform and app-based medical device—backed by 11 years of clinical validation—to accelerate and improve drug development, neurological disease research, and patient care.

By completing a 10-minute series of augmented reality and motor activities designed to simulate complex Activities of Daily Living on a smartphone or tablet, Altoida’s device extracts and provides robust measurements of neurocognitive function across 13 neurocognitive domains. Our device measures and analyzes nearly 800 multimodal cognitive and functional digital biomarkers. Through the collection of highly granular data from integrated smartphone or tablet sensors, Altoida’s device produces comprehensive neurocognitive domain scores. This data can be tracked longitudinally to reveal trends and patterns while flagging concerning ones.

Our approach, along with our innovative artificial intelligence, will pioneer fully digital predictive neurological disease diagnosis. After our Breakthrough Device designation by the FDA, Altoida’s device will provide patients with a predictive score that will enable a highly accurate prediction of whether a patient aged 55 and older will or will not convert from Mild Cognitive Impairment to Alzheimer’s disease.

To learn more about cataracts and dementia or Altoida’s Precision Neurology platform and medical device, contact us today.

Contact Us

At Altoida, we use digital biomarkers to radically change the method of assessing brain health and cognitive diseases. After nearly two decades of research, we are developing a platform and device to measure and analyze cognitive biomarkers associated with cognitive impairment to evaluate perceptual and memory function.
Contact Us

Contact Us

80 M Street SE, Suite 100 Washington, DC 20003 USA 

CONTACT@ALTOIDA.COM

Follow Us

Policy

By visiting our Website and/or using the Services in any manner, you acknowledge that you accept the practices and policies outlined in our Privacy Policy.


Our Disclaimer

@ Altoida 2022